NCT05832775View on ClinicalTrials.gov

Study to Assess the Safety of MRx0029 or MRx0005 Compared to Placebo, in People With Parkinson's

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2022

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2023

Conditions
Idiopathic Parkinson Disease
Interventions
BIOLOGICAL

MRx0029

Megasphaera massiliensis MRx0029 (Treatment A) and Placebo

BIOLOGICAL

MRx0005

Parabacteroides distasonis MRx0005 (Treatment B) and Placebo

Sponsors

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

Labcorp Corporation of America Holdings, Inc

INDUSTRY

collaborator

ICON plc

INDUSTRY

lead

4D pharma plc

INDUSTRY